

# THE PATIENT ACCESS PATHWAY


## LEGISLATIVE EFFECTS on patient access to medicines

The current administration has made it clear that the **repeal** of the Affordable Care Act is a serious priority. Now that the executive order has been signed, much as been made of the likely relative speed of new legislation. We won't prognosticate

on that. Instead, we give you a glimpse of the ways that patients along our patient access pathway are likely to be affected by this and a few other interesting pieces of legislation.

for more, follow our **patient access pathway**


### WELL CARE & DIAGNOSIS



**Legislation to watch**

Repeal of the ACA  
MACRA and CHIP post FY 2017  
Qualified Small Employer Health Reimbursement Arrangements (QSEHRA)

### PRESCRIPTION




**Legislation to watch**

S.124 - Preserve Access to Affordable Generics Act  
H.R.934 - Personal Drug Importation Fairness Act of 2017

### PA/UM



### Rx COVERAGE



**Legislation to watch**

The first actions in Energy and Commerce committee and The Ways and Means committee


### PATIENT ASSISTANCE



**Guidance to watch**

Office of Inspector General (OIG) Modification of Advisory Opinion 04-15; Modification of Advisory Opinion 07-11

### CARE CONTINUITY



**Legislation to watch**

The first actions in Energy and Commerce committee and The Ways and Means committee